These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Antithrombotic agents in pregnancy].
    Author: Gensini GF, Comeglio M, Abbate R.
    Journal: Cardiologia; 1994 Dec; 39(12 Suppl 1):357-65. PubMed ID: 7634297.
    Abstract:
    The need for antithrombotic therapy during pregnancy is a challenging problem for the clinician. Pregnancy per se is associated with a prothrombotic state, and some conditions definitely require anticoagulant treatment. However, all three main antithrombotic agents (coumarins, heparin and aspirin) have potential serious adverse effects for the mother and fetus. The aim of this review was to discuss the modifications of the coagulation system during pregnancy, and try to properly state the indications and the best schedule of antithrombotic treatment during pregnancy. Presently heparin is considered the anticoagulant of choice for the treatment and prevention of venous thromboembolic disorders and in patients with congenital or acquired thrombophilic conditions. The use of oral anticoagulants is still preferred in women with prosthetic heart valves or atrial fibrillation, but they cannot be administered between the sixth and twelfth week and in the last month of gestation because of the teratogenic and hemorrhagic risks related to their use. Low-dose aspirin is useful for the prevention of pre-eclampsia, intrauterin growth retardation, and in association with heparin or prednisone, for the prevention of abortion in patients with antiphospholipid antibodies.
    [Abstract] [Full Text] [Related] [New Search]